Skip to main content
SpringerLink
Log in
Book cover

Hodgkin Lymphoma pp 331–341Cite as

Allogeneic Transplantation for Relapsed Hodgkin Lymphoma

  • Chapter
  • First Online:

  • 1548 Accesses

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

Hodgkin lymphoma (HL) is highly responsive to conventional chemotherapy (CT). Close to 90 % of patients even with advanced disease are cured with modern CT sometimes followed by irradiation. Patients who prove refractory to or relapse after first-line therapy, do significantly worse. High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is the standard of care for medically fit patients with relapsed HL. The results of ASCT, however, vary significantly depending on a number of prognostic factors – the most important of which are the time interval between first-line treatment and relapse, the clinical stage at relapse, and the sensitivity of the tumor to salvage CT. More recently, the capacity to achieve a positron emission tomography (PET)-negative complete remission (CR) with the salvage regimen has also been demonstrated to be a good prognostic factor. For example, approximately 70 % of patients with late first relapse can be salvaged by HDT/ASCT, whereas not more than 40 % of patients suffering from early first relapse are rescued by this modality. Only 20–35 % of patients with refractory HL may achieve long-term survival after ASCT. In addition, a significant proportion of patients with HL still relapse after ASCT. Therefore, although HDT/ASCT may cure a significant proportion of patients with relapsed or refractory HL, subsets of patients carry a high risk of failure and are candidates for more experimental procedures such as allo-SCT.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin disease: mature results of a prospective clinical trial. J Clin Oncol 20:630–637

    Article  PubMed  Google Scholar 

  2. Diehl V, Franklin J, Pfreundschuh M et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin disease. N Engl J Med 348:2386–2395

    Article  CAS  PubMed  Google Scholar 

  3. Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin disease: results of a BNLI randomised trial. Lancet 341:1050–1054

    Article  Google Scholar 

  4. Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous haematopoietic stem cell transplantation for relapsed chemosensitive Hodgkin disease: a randomised trial. Lancet 359:2065–2071

    Article  CAS  PubMed  Google Scholar 

  5. Sureda A, Arranz R, Iriondo A et al (2001) Autologous stem cell transplantation for Hodgkin disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group. J Clin Oncol 19:1395–1404

    CAS  PubMed  Google Scholar 

  6. Lazarus HM, Loberiza FR, Zhang MJ et al (2001) Autotransplants for Hodgkin disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 27:387–396

    Article  CAS  PubMed  Google Scholar 

  7. Horning SJ, Chao NJ, Negrin RS et al (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin disease: analysis of the Stanford University results and prognostic indices. Blood 89:801–813

    CAS  PubMed  Google Scholar 

  8. Brice P, Bouabdallah R, Moreau P et al (1997) Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin disease: analysis of 280 patients from the French registry. Bone Marrow Transplant 20:21–26

    Article  CAS  PubMed  Google Scholar 

  9. Sweetenham JW, Taghipour G, Milligan D et al (1997) High-dose therapy and autologous stem cell rescue for patients with Hodgkin disease in first relapse after chemotherapy: results from the EBMT. Bone Marrow Transplant 20:745–752

    Article  CAS  PubMed  Google Scholar 

  10. Moskowitz AJ, Yahalom J, Kewalramani T et al (2010) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 116:4934–4937

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A (2000) Treatment of primary progressive Hodgkin and aggressive non-Hodgkin lymphoma: is there a chance for cure? J Clin Oncol 18:332–339

    CAS  PubMed  Google Scholar 

  12. Sweetenham JW, Carella AM, Taghipour (1999) High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. J Clin Oncol 17:3101–3109

    CAS  PubMed  Google Scholar 

  13. Lazarus HM, Rowlings PA, Zhang MJ et al (1999) Autotransplants for Hodgkin disease in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 17:534–545

    CAS  PubMed  Google Scholar 

  14. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96:1280–1286

    CAS  PubMed  Google Scholar 

  15. Appelbaum FR, Sullivan KM, Thomas ED et al (1985) Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin disease. J Clin Oncol 3:1490–1494

    CAS  PubMed  Google Scholar 

  16. Phillips GL, Reece DE, Barnett MJ et al (1989) Allogeneic marrow transplantation for refractory Hodgkin’s disease. J Clin Oncol 7:1039–1045

    CAS  PubMed  Google Scholar 

  17. Gajewski JL, Phillips GL, Sobocinski KA et al (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin disease. J Clin Oncol 14:572–578

    CAS  PubMed  Google Scholar 

  18. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin disease. J Clin Oncol 14:1291–1296

    CAS  PubMed  Google Scholar 

  19. Anderson JE, Litzow MR, Appelbaum FR et al (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin disease: the 21-year Seattle experience. J Clin Oncol 11:2342–2350

    CAS  PubMed  Google Scholar 

  20. Jones RJ, Ambinder RF, Piantadosi S, Santos GW (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649–653

    CAS  PubMed  Google Scholar 

  21. Akpek G, Ambinder RF, Piantadosi S et al (2001) Long-term results of blood and marrow transplantation for Hodgkin disease. J Clin Oncol 19:4314–4321

    CAS  PubMed  Google Scholar 

  22. Sureda A, Robinson S, Canals C et al (2008) Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:455–462

    Article  CAS  PubMed  Google Scholar 

  23. Corradini P, Zallio F, Mariotti J et al (2005) Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol 23:6690–6698

    Article  CAS  PubMed  Google Scholar 

  24. Burroughs LM, O’Donnell PV, Sandmaier BM et al (2008) Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Boil Bone Marrow Transplant 14:1279–1287

    Article  Google Scholar 

  25. Anderlini P, Saliba R, Acholonu S et al (2005) Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35:943–951

    Article  CAS  PubMed  Google Scholar 

  26. Faulkner RD, Craddock C, Byrne JL et al (2004) BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 103:428–434

    Article  CAS  PubMed  Google Scholar 

  27. Robinson SP, Goldstone AH, Mackinnon S et al (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310–4316

    Article  CAS  PubMed  Google Scholar 

  28. Peggs KS, Hunter A, Chopra R et al (2005) Clinical evidence of a graft-versus lymphoma effect after reduced intensity allogeneic transplantation. Lancet 365:1906–1908

    Article  Google Scholar 

  29. Alvarez I, Sureda A, Caballero D et al (2006) Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish Prospective Cooperative Protocol. Biol Bone Marrow Transplant 12:172–183

    Article  Google Scholar 

  30. Sureda A, Canals C, Arranz R et al (2012) Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study–a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 97:310–317

    Article  PubMed Central  PubMed  Google Scholar 

  31. Robinson SP, Sureda A, Canals C et al (2009) Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica 94:230–238

    Article  PubMed Central  PubMed  Google Scholar 

  32. Anderlini P, Saliba R, Acholonu S et al (2008) Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93:257–264

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Peggs KS, Kayani I, Edwards N et al (2011) Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin’s lymphoma. J Clin Oncol 29:971–978

    Article  CAS  PubMed  Google Scholar 

  34. Vose JM, Bierman PJ, Anderson JR et al (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80:2142–2148

    CAS  PubMed  Google Scholar 

  35. Varterasian M, Ratanatharathorn V, Uberti JP et al (1995) Clinical course and outcome of patients with Hodgkin’s disease who progress after autologous transplantation. Leuk Lymphoma 20:59–65

    Article  CAS  PubMed  Google Scholar 

  36. Smith SM, van Besien K, Carreras J et al (2008) Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Bone Marrow Transplant 14:904–912

    Article  Google Scholar 

  37. Carella AM, Beltrami G, Carella M Jr et al (2001) Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin’s disease. Haematologica 86:1121–1123

    CAS  PubMed  Google Scholar 

  38. Thomson KJ, Peggs KS, Smith P et al (2008) Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 41:765–770

    Article  CAS  PubMed  Google Scholar 

  39. Sarina B, Castagna L, Farina L et al (2010) Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 115:3671–3677

    Article  CAS  PubMed  Google Scholar 

  40. Thomson KJ, Kayani I, Ardeshna K et al (2013) A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma. Leukemia 27:1419–1422

    Article  CAS  PubMed  Google Scholar 

  41. Claviez A, Klingebiel T, Beyer J et al (2004) Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin disease. Ann Hematol 83:237–241

    Article  PubMed  Google Scholar 

  42. Claviez A, Canals C, Dierickx D et al (2009) Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 114:2060–2067

    Article  CAS  PubMed  Google Scholar 

  43. Devetten MP, Hari PN, Carreras J et al (2009) Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Bone Marrow Transplant 15:109–117

    Article  Google Scholar 

  44. Majhail NS, Weisdorf DJ, Wagner JE et al (2006) Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 107:3804–3807

    Article  CAS  PubMed  Google Scholar 

  45. Rodrigues CA, Sanz G, Brunstein CG et al (2009) Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 27:256–263

    Article  PubMed  Google Scholar 

  46. Rodrigues CA, Rocha V, Dreger P et al (2014) Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. Haematologica 99:370–377

    Article  PubMed Central  PubMed  Google Scholar 

  47. Marcais A, Porcher R, Robin M et al (2013) Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin’s lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Haematologica 98:1467–1475

    Article  PubMed Central  PubMed  Google Scholar 

  48. Raiola A, Dominietto A, Varaldo R et al (2014) Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma. Bone Marrow Transplant 49:190–194

    Article  CAS  PubMed  Google Scholar 

  49. Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30:2183–2189

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Chen R, Palmer JM, Thomas SH et al (2012) Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 119:6379–6381

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Chen R, Palmer J, Tsai NC et al (2013) Brentuximab vedotin improves HCT-CI, CR status, and peri-transplant toxicity in patients with relapsed/refractory Hodgkin lymphoma heading to RIC Allo-HCT. Blood 122:3374

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Institut Català d’Oncologia – Hospital Duran I Reynals, Avda. Gran Vía 199-203, Barcelona, L’Hospitalet de Llobregat, 08908, Spain

    Anna Sureda MD

  2. Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Mas Casanovas, 90, Barcelona, 08025, Spain

    Anna Sureda MD

  3. Department of Haematology, Cancer Institute, University College London, Pond Street, London, NW3 2QG, UK

    Stephen Mackinnon

  4. Department of Haematology, Royal Free Hospital, Pond Street, London, NW3 2QG, UK

    Stephen Mackinnon

Authors
  1. Anna Sureda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen Mackinnon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen Mackinnon .

Editor information

Editors and Affiliations

  1. Universitätsklinikum Köln Klinik I für Innere Medizin, Köln, Germany

    Andreas Engert

  2. Memorial Sloan - Kettering Cancer Center, New York, New York, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing

About this chapter

Cite this chapter

Sureda, A., Mackinnon, S. (2015). Allogeneic Transplantation for Relapsed Hodgkin Lymphoma. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-12505-3_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12505-3_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12504-6

  • Online ISBN: 978-3-319-12505-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation